Epigenetic mechanisms in schizophrenia

Progress in Biophysics and Molecular Biology

Volumn 118, Issue 1-2, 2015, Pages 1-7

  Shorter, Kimberly R ^a   Miller, Brooke H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

DNA methylation; Epigenetics; Histones; MicroRNA; Neurodevelopment; Schizophrenia

Indexed keywords

CHROMATIN; HISTONE; MICRORNA;

ANIMAL; CHROMATIN; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; SCHIZOPHRENIA;

ANIMALS; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; SCHIZOPHRENIA;

EID: 84930539754     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.04.008     Document Type: Review

References (94)

1. Abdolmaleky H.M., Ahmadkhaniha H.R., Nohesara S., Smith C.L. Epigenetic and genetic aberrations of the brain dopaminergic system in schizophrenia and bipolar disorder: achievements and prospective. Iran. J. Psychiatry Behav. Sci. 2008, 2:4-13.
2. Abdolmaleky H.M., Cheng K.H., Faraone S.V., Wilcox M., Glatt S.J., Gao F., Smith C.L., Shafa R., Aeali B., Carnevale J., Pan H., Papageorgis P., Ponte J.F., Sivaraman V., Tsuang M.T., Thiagalingam S. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2006, 15:3132-3145.
3. Abdolmaleky H.M., Smith C.L., Faraone S.V., Shafa R., Stone W., Glatt S.J., Tsuang M.T. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am. J. Med. Genet. Part B (Neuropsychiatr. Genet. 2004, 127B:51-59.
4. Akbarian S. The molecular pathology of schizophrenia-focus on histone and DNA modifications. Brain Res. Bull. 2010, 83:103-107.
5. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
6. Ausio J., de Paz A.M., Esteller M. MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol. Med. 2014, 1-12.
7. Bagot R.C., Zhang T.Y., Wen X., Nguyen T.T., Nguyen H.B., Diorio J., Wong T.P., Meaney M.J. Variations in postnatal maternal care and the epigenetic regulation of metabotropic glutamate receptor 1 expression and hippocampal function in the rat. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(Suppl.2):17200-17207.
8. Bale T.L., Baram T.Z., Brown A.S., Goldstein J.M., Insel T.R., McCarthy M.M., Nemeroff C.B., Reyes T.M., Simerly R.B., Susser E.S., Nestler E.J. Early life programming and neurodevelopmental disorders. Biol. Psychiatry 2010, 68:314-319.
9. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13:76-83.
10. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10164-10169.
11. Benneyworth M.A., Roseman A.S., Basu A.C., Coyle J.T. Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Neurosci. Lett. 2011, 488:267-271.
12. Bhatt D.H., Zhang S., Gan W.B. Dendritic spine dynamics. Annu Rev. Physiol. 2009, 71:261-282.
13. Blot K., Bai J., Otani S. The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: an animalmodel for cognitive symptoms of schizophrenia. J.Physiol. Paris 2013, 107:448-451.
14. Boley A.M., Perez S.M., Lodge D.J. Afundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. Schizophr. Res. 2014, 157:238-243.
15. Bonsch D., Wunschel M., Lenz B., Janssen G., Weisbrod M., Sauer H. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Res. 2012, 198:533-537.
16. Brucato N., DeLisi L.E., Fisher S.E., Francks C. Hypomethylation of the paternally inherited LRRTM1 promoter linked to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2014, 165:555-563.
17. Buxbaum J.D., Silverman J.M., Smith C.J., Greenberg D.A., Kilifarski M., Reichert J., Cook E.H., Fang Y., Song C.Y., Vitale R. Association between a GABRB3 polymorphism and autism. Mol. Psychiatry 2002, 7:311-316.
18. Carrier F., Georgel P.T., Pourquier P., Blake M., Kontny H.U., Antinore M.J., Gariboldi M., Myers T.G., Weinstein J.N., Pommier Y., Fornace A.J. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol. Cell. Biol. 1999, 19:1673-1685.
19. Ceaser A., Csernansky J.G., Barch D.M. COMT influences on prefrontal and striatal blood oxygenation level-dependent responses during working memory among individuals with schizophrenia, their siblings, and healthy controls. Cogn. Neuropsychiatry 2013, 18:257-283.
20. Chase K.A., Gavin D.P., Guidotti A., Sharma R.P. Histone methylation at H3K9: evidence for a restrictive epigenome in schizophrenia. Schizophr. Res. 2013, 149:15-20.
21. Cheng L.C., Pastrana E., Tavazoie M., Doetsch F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 2009, 12(4):399-408.
22. Cole D.M., Oei N.Y., Soeter R.P., Both S., van Gerven J.M., Rombouts S.A., Beckmann C.F. Dopamine-dependent architecture of cortico-subcortical network connectivity. Cereb. Cortex 2013, 23:1509-1516.
23. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-1379. Consortium, C.-D.G.o.t.P.G.
24. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976. Consortium, S.P.G.-W.A.S.
25. Cortellino S., Xu J., Sannai M., Moore R., Caretti E., Cigliano A., Le Coz M., Devarajan K., Wessels A., Soprano D., Abramowitz L.K., Bartolomei M.S., Rambow F., Bassi M.R., Bruno T., Fanciulli M., Renner C., Klein-Szanto A.J., Matsumoto Y., Kobi D., Davidson I., Alberti C., Larue L., Bellacosa A. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146:67-79.
26. Craddock N., Sklar P. Genetics of bipolar disorder. Lancet 2013, 381:1654-1662.
27. Cummings E., Donohoe G., Hargreaves A., Moore S., Fahey C., Dinan T.G., McDonald C., O'Callaghan E., O'Neill F.A., Waddington J.L., Murphy K.C., Morris D.W., Gill M., Corvin A. Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci. Lett. 2013, 532:33-38.
28. David H.N., Ansseau M., Abraini J.H. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res. Brain Res. Rev. 2005, 50:336-360.
29. Dempster E.L., Pidsley R., Schalkwyk L.C., Owens S., Georgiades A., Kane F., Kalidindi S., Picchioni M., Kravariti E., Toulopoulou T., Murray R.M., Mill J. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum. Mol. Genet. 2011, 20:4786-4796.
30. Dong E., Gavin D.P., Chen Y., Davis J. Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Transl. Psychiatry 2012, 2:e159.
31. Enomoto T., Noda Y., Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find. Exp. Clin. Pharmacol. 2007, 29:291-301.
32. Flames N., Long J.E., Garratt A.N., Fischer T.M., Gassmann M., Birchmeier C., Lai C., Rubenstein J.L., Marín O. Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron 2004, 44:251-261.
33. Gavin D.P., Akbarian S. Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease. Neurobiol. Dis. 2012, 46:255-262.
34. Gavin D.P., Rosen C., Chase K., Grayson D.R., Tun N., Sharma R.P. Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures. J.Psychiatry Neurosci. 2009, 34:232-237.
35. Geddes A.E., Huang X.F., Newell K.A. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:896-904.
36. Ghadirivasfi M., Nohesara S., Ahmadkhaniha H.R., Eskandari M.R., Mostafavi S., Thiagalingam S., Abdolmaleky H.M. Hypomethylation of the serotonin receptor type-2A gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B:536-545.
37. Gilani A.I., Chohan M.O., Inan M., Schobel S.A., Chaudhury N.H., Paskewitz S., Chuhma N., Glickstein S., Merker R.J., Xu Q., Small S.A., Anderson S.A., Ross M.E., Moore H. Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal disinhibition. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:7450-7455.
38. Gilman S.R., Chang J., Xu B., Bawa T.S., Gogos J.A., Karayiorgou M., Vitkup D. Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat. Neurosci. 2012, 15:1723-1728.
39. Goffin D., Allen M., Zhang L., Amorim M., Wang I.-T.J., Reyes A.-R.S., Mercado-Berton A., Ong C., Cohen S., Hu L., Blendy J.A., Carlson G.C., Siegel S.J., Greenberg M.E., Zhou Z. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 2012, 15:274-283.
40. Gogos J.A., Gerber D.J. Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol. Sci. 2006, 27:226-233.
41. Grayson D.R., Guidotti A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsychopharmacology 2013, 38:138-166.
42. Grayson D.R., Jia X., Chen Y., Sharma R.P., Mitchell C.P., Guidotti A., Costa E. Reelin promoter hypermethylation in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9341-9346.
43. Guidotti A., Auta J., Davis J.M., Dong E., Gavin D.P., Grayson D.R., Sharma R.P., Smith R.C., Tueting P., Zhubi A. Toward the identification of peripheral epigenetic biomarkers of schizophrenia. J.Neurogenet. 2014, 28:41-52.
44. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
45. Hall J., Trent S., Thomas K.L., O'Donovan M.C., Owen M.J. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol. Psychiatry 2014, 77(1):52-58.
46. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J.G., Morris H.M., Volk D.W., Mirnics K., Lewis D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2008, 13:147-161.
47. Herrera A.S., Casanova J.P., Gatica R.I., Escobar F., Fuentealba J.A. Clozapine pre-treatment has a protracted hypolocomotor effect on the induction and expression of amphetamine sensitization. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 47:1-6.
48. Hill M.J., Donocik J.G., Nuamah R.A., Mein C.A., Sainz-Fuertes R., Bray N.J. Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells. Schizophr. Res. 2014, 153:225-230.
49. Ingason A., Kirov G., Giegling I., Hansen T., Isles A.R., Jakobsen K.D., Kristinsson K.T., le Roux L., Gustafsson O., Craddock N., Möller H.J., McQuillin A., Muglia P., Cichon S., Rietschel M., Ophoff R.A., Djurovic S., Andreassen O.A., Pietiläinen O.P., Peltonen L., Dempster E., Collier D.A., St Clair D., Rasmussen H.B., Glenthøj B.Y., Kiemeney L.A., Franke B., Tosato S., Bonetto C., Saemundsen E., Hreidarsson S.J., Nöthen M.M., Gurling H., O'Donovan M.C., Owen M.J., Sigurdsson E., Petursson H., Stefansson H., Rujescu D., Stefansson K., Werge T., Investigators G. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am. J. Psychiatry 2011, 168:408-417.
50. Johnstone K.A., DuBose A.J., Futtner C.R., Elmore M.D., Brannan C.I., Resnick J.L. Ahuman imprinting centre demonstrates conserved acquisition but diverged maintenance of imprinting in a mouse model for Angelman syndrome imprinting defects. Hum. Mol. Genet. 2006, 15:393-404.
51. Kalkman H.O., Loetscher E. GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. J.Neural Transm. 2003, 110:803-812.
52. Kato T., Iwamoto K. Comprehensive DNA methylation and hydroxymethylation analysis in the human brain and its implication in mental disorders. Neuropharmacology 2014, 80:133-139.
53. Kosik K.S. The neuronal microRNA system. Nat. Rev. Neurosci. 2006, 7:911-920.
54. Kosower N.S., Gerad L., Goldstein M., Parasol N., Zipser Y., Ragolsky M., Rozencwaig S., Elkabetz E., Abramovitch Y., Lerer B. Constitutive heterochromatin of chromosome 1 and duffy blood group alleles in schizophrenia. Am. J. Med. Genet. 1995, 60:133-138.
55. Kundakovic M., Chen Y., Guidotti A., Grayson D.R. The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol. Pharmacol. 2009, 75:342-354.
56. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
57. Lewis D.A., Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev. Neurosci. 2002, 25:409-432.
58. Lintas C., Persico A.M. Neocortical RELN promoter methylation increases significantly after puberty. Neuroreport 2010, 21:114-118.
59. Lott S.A., Burghardt P.R., Burghardt K.J., Bly M.J., Grove T.B., Ellingrod V.L. The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J. 2013, 13:264-271.
60. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
61. Matrisciano F., Tueting P., Dalal I., Kadriu B., Grayson D.R., Davis J.M., Nicoletti F., Guidotti A. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology 2013, 68:184-194.
62. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonte B., Szyf M., Turecki G., Meaney M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12:342-348.
63. McGuffin P., Gottesman I.I. Risk factors for schizophrenia. N.Engl. J. Med. 1999, 341:370-371. author reply 372.
64. Miller B.H., Wahlestedt C. MicroRNA dysregulation in psychiatric disease. Brain Res. 2010, 89-99.
65. Miller B.H., Zeier Z., Xi L., Lanz T.A., Deng S., Strathmann J., Willoughby D., Kenny P.J., Elsworth J.D., Lawrence M.S., Roth R.H., Edbauer D., Kleiman R.J., Wahlestedt C. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3125-3130.
66. Mitchelmore C., Gede L. Brain derived neurotrophic factor: epigenetic regulation in psychiatric disorders. Brain Res. 2014, 1586:162-172.
67. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
68. Monteggia L.M., Kavalali E.T. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol. Psychiatry 2009, 65:204-210.
69. Neill J.C., Harte M.K., Haddad P.M., Lydall E.S., Dwyer D.M. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur. Neuropsychopharmacol. 2014, 24:822-835.
70. Rai K., Huggins I.J., James S.R., Karpf A.R., Jones D.A., Cairns B.R. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008, 135:1201-1212.
71. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 2012, 17:1228-1238.
72. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., Scolnick E., Cichon S., St Clair D., Corvin A., Gurling H., Werge T., Rujescu D., Blackwood D.H., Pato C.N., Malhotra A.K., Purcell S., Dudbridge F., Neale B.M., Rossin L., Visscher P.M., Posthuma D., Ruderfer D.M., Fanous A., Stefansson H., Steinberg S., Mowry B.J., Golimbet V., De Hert M., Jonsson E.G., Bitter I., Pietilainen O.P., Collier D.A., Tosato S., Agartz I., Albus M., Alexander M., Amdur R.L., Amin F., Bass N., Bergen S.E., Black D.W., Borglum A.D., Brown M.A., Bruggeman R., Buccola N.G., Byerley W.F., Cahn W., Cantor R.M., Carr V.J., Catts S.V., Choudhury K., Cloninger C.R., Cormican P., Craddock N., Danoy P.A., Datta S., de Haan L., Demontis D., Dikeos D., Djurovic S., Donnelly P., Donohoe G., Duong L., Dwyer S., Fink-Jensen A., Freedman R., Freimer N.B., Friedl M., Georgieva L., Giegling I., Gill M., Glenthoj B., Godard S., Hamshere M., Hansen M., Hansen T., Hartmann A.M., Henskens F.A., Hougaard D.M., Hultman C.M., Ingason A., Jablensky A.V., Jakobsen K.D., Jay M., Jurgens G., Kahn R.S., Keller M.C., Kenis G., Kenny E., Kim Y., Kirov G.K., Konnerth H., Konte B., Krabbendam L., Krasucki R., et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
73. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 2005, 6:597-610.
74. Robertson K.D., Wolffe A.P. DNA methylation in health and disease. Nat. Rev. Genet. 2000, 1:11-19.
75. Salavati B., Rajji T.K., Price R., Sun Y., Graff-Guerrero A., Daskalakis Z.J. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr. Bull. 2014, 41(1):44-56.
76. Schanen N.C. Epigenetics of autism spectrum disorders. Hum. Mol. Genet. 2006, 15(2):R138-R150.
77. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 2010, 4:56-73.
78. Sharma R.P., Grayson D.R., Gavin D.P. Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the national brain databank microarray collection. Schizophr. Res. 2008, 98:111-117.
79. Stark K.L., Xu B., Bagchi A., Lai W.S., Liu H., Hsu R., Wan X., Pavlidis P., Mills A.A., Karayiorgou M., Gogos J.A. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat. Genet. 2008, 40:751-760.
80. Svensson T.H. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res. Brain Res. Rev. 2000, 31:320-329.
81. Szulwach K.E., Li X., Smrt R.D., Li Y., Luo Y., Lin L., Santistevan N.J., Li W., Zhao X., Jin P. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J.Cell. Biol. 2010, 189:127-141.
82. Tan H.Y., Callicott J.H., Weinberger D.R. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb. Cortex 2007, 17(Suppl.1):i171-i181.
83. Tan H.Y., Chen A.G., Chen Q., Browne L.B., Verchinski B., Kolachana B., Zhang F., Apud J., Callicott J.H., Mattay V.S., Weinberger D.R. Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Mol. Psychiatry 2012, 17:1007-1016.
84. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 2007, 8:355-367.
85. Uchida T., Furukawa T., Iwata S., Yanagawa Y., Fukuda A. Selective loss of parvalbumin-positive GABAergic interneurons in the cerebral cortex of maternally stressed Gad1-heterozygous mouse offspring. Transl. Psychiatry 2014, 4:e371.
86. Valenti O., Cifelli P., Gill K.M., Grace A.A. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J.Neurosci. 2011, 31:12330-12338.
87. van Erp T.G., Guella I., Vawter M.P., Turner J., Brown G.G., McCarthy G., Greve D.N., Glover G.H., Calhoun V.D., Lim K.O., Bustillo J.R., Belger A., Ford J.M., Mathalon D.H., Diaz M., Preda A., Nguyen D., Macciardi F., Potkin S.G. Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. Biol. Psychiatry 2014, 75:398-405.
88. Wang H., An W., Cao R., Xia L., Erdjument-Bromage H., Chatton B., Tempst P., Roeder R.G., Zhang Y. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol. Cell. 2003, 12:475-487.
89. Weaver I.C., Meaney M.J., Szyf M. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3480-3485.
90. Wong J., Hyde T.M., Cassano H.L., Deep-Soboslay A., Kleinman J.E., Weickert C.S. Promoter specific alterations of brain-derived neurotrophic factor Mrna in schizophrenia. Neuroscience 2010, 169:1071-1084.
91. Xiao Y., Camarillo C., Ping Y., Arana T.B., Zhao H., Thompson P.M., Xu C., Su B.B., Fan H., Ordonez J., Wang L., Mao C., Zhang Y., Cruz D., Escamilla M.A., Li X. The DNA methylome and transcriptome of different brain regions in schizophrenia and bipolar disorder. PLoS One 2014, 9:e95875.
92. Yasui D.H., Scoles H.A., Horike S., Meguro-Horike M., Dunaway K.W., Schroeder D.I., Lasalle J.M. 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain. Hum. Mol. Genet. 2011, 20:4311-4323.
93. Zee B.M., Levin R.S., Xu B., LeRoy G., Wingreen N.S., Garcia B.A. Invivo residue-specific histone methylation dynamics. J.Biol. Chem. 2010, 285:3341-3350.
94. Zhang T.Y., Hellstrom I.C., Bagot R.C., Wen X., Diorio J., Meaney M.J. Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus. J.Neurosci. 2010, 30:13130-13137.